Background: Curcuma longa L., commonly known as turmeric, is renowned for its therapeutic benefits attributed to bioactive compounds, namely curcumin (Cur) and aromatic turmerone (Tur), present in its rhizome. These compounds exhibit diverse therapeutic properties, including anti-inflammatory, antioxidant, and anti-tumor effects. However, the topical application of these compounds has a significant potential for inducing skin irritation. This study focuses on formulating solid lipid nanoparticle (SLN) carriers encapsulating both Cur and Tur for reduced irritation and enhanced stability. Methods: SLN formulations were prepared by a method using homogenization followed by ultrasonication procedures and optimized by applying response surface methodology (RSM). Results: The optimized SLN formulation demonstrated entrapment efficiencies, with 77.21 ± 4.28% for Cur and 75.12 ± 2.51% for Tur. A size distribution of 292.11 ± 9.43 nm was obtained, which was confirmed to be a spherical and uniform shape via environmental scanning electron microscopy (ESEM) images. The in vitro release study indicated cumulative releases of 71.32 ± 3.73% for Cur and 67.23 ± 1.64% for Tur after 24 hours under sink conditions. Physical stability tests confirmed the stability of formulation, allowing storage at 4°C for a minimum of 60 days. Notably, in vitro skin irritation studies, utilizing the reconstructed human epidermal model (EPI-200-SIT), revealed a significant reduction in irritation with the SLN containing Cur and Tur compared to nonencapsulated Cur and Tur. Conclusion: These findings collectively endorse the optimized SLN formulation as a favorable delivery system for Cur and Tur in diverse topical uses, offering enhanced stability, controlled release and reduced irritation.
Background/Objectives: Wound healing is a complex biological process influenced by inflammation, oxidative stress, and cellular regeneration. Plant-derived bioactive compounds have shown potential to accelerate tissue repair through antioxidant and anti-inflammatory mechanisms. This study aimed to develop and evaluate a Platanus orientalis extract-loaded liposomal formulation for potential wound-healing applications. Methods: Four polar extracts (P1–P4) were prepared using different solvent systems and extraction techniques and were characterized by LC-HRMS to determine their phytochemical profiles. Among the identified constituents, quercetin was consistently detected across all extracts and selected as the reference compound due to its well-known wound-healing activity. Liposomes were prepared via thin-film hydration followed by probe sonication and characterized for particle size, polydispersity index (PDI), zeta potential, encapsulation efficiency, and total drug content. In vitro release, cytotoxicity, and wound-healing assays were subsequently conducted to assess performance. Results: The optimized liposome formulation had a mean particle size of 106.6 ± 5.4 nm, a PDI of 0.11 ± 0.04, and a zeta potential of −14.1 ± 0.5 mV. Environmental scanning electron microscopy (ESEM) confirmed the nanosized spherical morphology and homogeneous vesicle distribution, supporting the successful development of the liposomal delivery system. Encapsulation efficiency and total drug content were determined as 72.25 ± 1.05% and 96.15 ± 0.14%, respectively. In vitro release studies demonstrated a biphasic pattern with an initial burst followed by a sustained release, reaching approximately 75% cumulative quercetin release within 24 h. Physical stability testing confirmed that the optimized liposomal formulation remained physically stable at 5 ± 3 °C for at least 60 days. The optimized formulation showed no cytotoxic effects on CDD-1079Sk fibroblast cells and exhibited significantly enhanced wound closure in vitro. Conclusions: These findings indicate that the liposomal delivery of Platanus orientalis extract provides a biocompatible and sustained-release system that enhances wound-healing efficacy, supporting its potential use in advanced topical therapeutic applications.
This study investigates the encapsulation of bakuchiol, a renowned compound for hyperpigmentation treatment, utilizing transfersomes as a delivery system. The transfersomes were fabricated using the thin-film hydration technique and subjected to thorough characterization across various parameters. The resulting transfersome formulation, after optimization, demonstrated notably high encapsulation efficiencies, with bakuchiol registering at 86.7±3.6%, accompanied by a narrow particle size distribution (179.9 ± 5.4 nm). In vitro release studies unveiled cumulative release percentages of 71.98±6.52% for bakuchiol over a 24-hour period. Ex vivo permeation studies further affirmed heightened retention of bakuchiol within the skin layers compared to control group. Stability assessments indicated that the optimized transfersome remained stable at 5°C for at least 90 days. These findings underscore the remarkable potential of transfersomes in facilitating the delivery of bakuchiol, offering a compelling and viable alternative for hyperpigmentation formulations.